Aandeel BIOBLAST PHARMA LTD
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren
Inactief instrument

Andere talen Bioblast Pharma Ltd Nasdaq

Aandelen

IL0011319527

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!
Gratis inschrijven
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
Enlivex Therapeutics : Immediate Report
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
Enlivex Therapeutics to Launch Registered Direct Offering; Shares Fall
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
Enlivex Therapeutics : Report of Periodic or Interim Report
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
Enlivex Therapeutics Says First Two Patients Dosed in Knee Osteoarthritis Trial
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
Enlivex Therapeutics Ltd. Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra? in Patients with Knee Osteoarthritis
Enlivex Therapeutics Receives Approval to Expand Trial of Allocetra to Treat Knee Osteoarthritis Into Denmark
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
Enlivex Therapeutics Ltd Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
Sector Update: Health Care Stocks Softer Late Afternoon
Sector Update: Health Care
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
Enlivex Therapeutics Shares Fall After Topline Data from Sepsis Treatment Study
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers ENLV
  4. Koers
  5. Nieuws Bioblast Pharma Ltd
  6. Andere talen